Better Coronavirus Stock: Pfizer vs. BioNTech
Mercedes or Porsche? Steak or sushi? Two things can both be good but very different. For investors, the best coronavirus stock may depend on who's choosing. Breaking down the pros and cons of Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) reveals two very different companies linked by more than their partnership on a COVID-19 vaccine. So how do you choose between buying these two stocks, or do you really have to?
Image source: Getty Images.
Pfizer and BioNTech are at opposite ends of the spectrum in terms of corporate lifespans. As a $218 billion company founded 170 years ago, Pfizer is about as old as companies get. With 92 treatments in various stages of clinical trials and 49 individual drugs generating $52 billion in revenue, Pfizer is the definition of a blue-chip stock. Perhaps because those sales sit exactly where they were in 2013, the company has been transforming itself. The moves include merging Upjohn, its off-patent drugs division, with Mylan to form a new entity named Viatris (NASDAQ: VTRS). With a renewed focus on more profitable oncology drugs and vaccines, Pfizer's management is betting that growth will return.
Source Fool.com
